Regulatory T cell therapy as individualized medicine for asthma and allergy

Current Opinion in Allergy and Clinical Immunology

Volumn 7, Issue 6, 2007, Pages 535-541

  Xystrakis, Emmanuel ^a   Urry, Zoë ^a   Hawrylowicz, Catherine M ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Allergy; IL 10; Regulatory T cells

Indexed keywords

GLUCOCORTICOID; IMMUNOGLOBULIN E; INTERLEUKIN 10; INTERLEUKIN 4; RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ALLERGY; ASTHMA; CD25+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL POPULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; GRAFT REJECTION; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; UNSPECIFIED SIDE EFFECT;

ADOPTIVE TRANSFER; ANIMALS; ASTHMA; DISEASE MODELS, ANIMAL; HUMANS; HYPERSENSITIVITY; T-LYMPHOCYTES, REGULATORY;

EID: 35948991877     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3282f14d7c     Document Type: Review

References (72)

1. Kay AB. Allergy and allergic diseases: second of two parts. N Engl J Med 2001; 344:109-113.
2. Kay AB. Allergy and allergic diseases: first of two parts. N Engl J Med 2001; 344:30-37.
3. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22:531-562.
4. Shevach E. CD4+CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2004; 2:389-400.
5. O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 2004; 10:801-805.
6. Banham AH, Powrie FM, Suri-Payer E. FOXP3+ regulatory T cells: current controversies and future perspectives. Eur J Immunol 2006; 36:2832-2836.
7. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 203:1701-1711. This paper identifies that expression of CD127 can be used to discriminate between human regulatory and activated T cells. The capacity to identify and track natural Tregs in patients would represent a major advance in our capacity to study these cells in human disease.
8. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203:1693-1700. This paper identifies that expression of CD127 can be used to discriminate between human regulatory and activated T cells. The capacity to identify and track natural Tregs in patients would represent a major advance in our capacity to study these cells in human disease.
9. Cosmi L, Liotta F, Angeli R, et al. Th2 cells are less susceptible than Th1 cells to the suppressive activity of CD25+ regulatory thymocytes because of their responsiveness to different cytokines. Blood 2004; 103:3117-3121.
10. Stassen M, Jonuleit H, Muller C, et al. Differential regulatory capacity of CD25+ T regulatory cells and preactivated CD25+ T regulatory cells on development, functional activation, and proliferation of Th2 cells. J Immunol 2004; 173:267-274.
11. Williams LM, Rudensky AY. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol 2007; 8:277-284.
12. Gavin MA, Rasmussen JP, Fontenot JD, et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 2007; 445:771-775.
13. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 2007; 8:191-197.
14. Gavin MA, Torgerson TR, Houston E, et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci U S A 2006; 103:6659-6664.
15. Allan SE, Crome SQ, Crellin NK, et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007; 19:345-354.
16. Wang J, Ioan-Facsinay A, van der Voort EI, et al. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007; 37:129-138.
17. Campbell DJ, Ziegler SF. FOXP3 modifies the phenotypic and functional properties of regulatory T cells. Nat Rev Immunol 2007; 7:305-310.
18. Lin W, Haribhai D, Relland LM, et al. Regulatory T cell development in the absence of functional Foxp3. Nat Immunol 2007; 8:359-368.
19. Bacchetta R, Passerini L, Gambineri E, et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest 2006; 116:1713-1722. This is one of a series of papers that are the most recent to describe mutations leading to loss of the natural Treg compartment in humans resulting in immune-mediated pathology including allergy.
20. Torgerson TR, Linane A, Moes N, et al. Severe food allergy as a variant of IPEX syndrome caused by a deletion in a noncoding region of the FOXP3 gene. Gastroenterology 2007; 132:1705-1717. This is one of a series of papers that are the most recent to describe mutations leading to loss of the natural Treg compartment in humans resulting in immune-mediated pathology including allergy.
21. Caudy AA, Reddy ST, Chatila T, et al. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J Allergy Clin Immunol 2007; 119:482-487. This is one of a series of papers that are the most recent to describe mutations leading to loss of the natural Treg compartment in humans (it is unclear whether this represents a loss of natural or adaptive Treg) resulting in immune-mediated pathology including allergy.
22. Maillard MH, Cotta-de-Almeida V, Takeshima F, et al. The Wiskott-Aldrich syndrome protein is required for the function of CD4(+)CD25(+)Foxp3(+) regulatory T cells. J Exp Med 2007; 204:381-391. This is one of a series of papers that are the most recent to describe mutations leading to loss of the natural Treg compartment in humans (it is unclear whether this represents a loss of natural or adaptive Treg) resulting in immune-mediated pathology including allergy.
23. Marangoni F, Trifari S, Scaramuzza S, et al. WASP regulates suppressor activity of human and murine CD4(+)CD25(+)FOXP3(+) natural regulatory T cells. J Exp Med 2007; 204:369-380. This is one of a series of papers that are the most recent to describe mutations leading to loss of the natural Treg compartment in humans (it is unclear whether this represents a loss of natural or adaptive Treg) resulting in immune-mediated pathology including allergy.
24. Ling EM, Smith T, Nguyen XD, et al. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004; 363:608-615.
25. Grindebacke H, Wing K, Andersson AC, et al. Defective suppression of Th2 cytokines by CD4CD25 regulatory T cells in birch allergics during birch pollen season. Clin Exp Allergy 2004; 34:1364-1372.
26. Bellinghausen I, Klostermann B, Knop J, Saloga J. Human CD4+CD25+ T cells derived from the majority of atopic donors are able to suppress TH1 and TH2 cytokine production. J Allergy Clin Immunol 2003; 111:862-868.
27. Xystrakis E, Boswell SE, Hawrylowicz CM. T regulatory cells and the control of allergic disease. Expert Opin Biol Ther 2006; 6:121-133.
28. Hartl D, Koller B, Mehlhorn AT, et al. Quantitative and functional impairment of pulmonary CD4+CD25hi regulatory T cells in pediatric asthma. J Allergy Clin Immunol 2007; 119:1258-1266. Some, but not all, earlier studies have suggested impaired function of natural Tregs in allergic patients. A limitation of these studies was that Tregs were derived from peripheral blood and not the active site of disease. This paper, importantly, studies natural Tregs isolated from the active site of disease and clearly demonstrates quantitative and functional impairment of natural Tregs.
29. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003; 299:1033-1036.
30. Doganci A, Eigenbrod T, Krug N, et al. The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J Clin Invest 2005; 115:313-325.
31. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 2007; 204:33-39. This paper demonstrates that inflammatory cytokines impair natural Treg function in human disease.
32. Valencia X, Stephens G, Goldbach-Mansky R, et al. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006; 108:253-261. This paper demonstrates that inflammatory cytokines impair natural Treg function in human disease.
33. Ruprecht CR, Gattorno M, Ferlito F, et al. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J Exp Med 2005; 201:1793-1803.
34. Chen X, Oppenheim JJ, Winkler-Pickett RT, et al. Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3(+)CD4(+)CD25(+) T regulatory cells in vivo and enhances their capacity to suppress EAE. Eur J Immunol 2006; 36:2139-2149. This paper suggests the capacity of commonly used anti-inflammatory agents to promote natural Treg activity.
35. Dao Nguyen X, Robinson DS. Fluticasone propionate increases CD4CD25 T regulatory cell suppression of allergen-stimulated CD4CD25 T cells by an IL-10-dependent mechanism. J Allergy Clin Immunol 2004; 114:296-301.
36. Karagiannidis C, Akdis M, Holopainen P, et al. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol 2004; 114:1425-1433.
37. Battaglia M, Stabilini A, Migliavacca B, et al. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006; 177:8338-8347. This paper suggests the capacity of commonly used anti-inflammatory agents to promote natural Treg activity.
38. You S, Leforban B, Garcia C, et al. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A 2007; 104:6335-6340.
39. Apostolou I, von Boehmer H. In vivo instruction of suppressor commitment in naive T cells. J Exp Med 2004; 199:1401-1408.
40. Kretschmer K, Apostolou I, Hawiger D, et al. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 2005; 6:1219-1227.
41. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol 2005; 6:338-344.
42. Benson MJ, Pino-Lagos K, Rosemblatt M, Noelle RJ. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med 2007; 204:1765-1774. Natural Tregs were originally described to derive from the thymus and play a key role in maintaining immunological tolerance to self. This paper now identifies a pathway for the peripheral induction, in the gut, of Foxp3+ Treg specific for environmental antigens.
43. Sun CM, Hall JA, Blank RB, et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med 2007; 204:1775-1785. Natural Tregs were originally described to derive from the thymus and play a key role in maintaining immunological tolerance to self. This paper now identifies a pathway for the peripheral induction, in the gut, of Foxp3+ Treg specific for environmental antigens.
44. Coombes JL, Siddiqui KR, Arancibia-Carcamo CV, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-β- and retinoic acid-dependent mechanism. J Exp Med 2007; 204:1757-1764. Natural Tregs were originally described to derive from the thymus and play a key role in maintaining immunological tolerance to self. This paper now identifies a pathway for the peripheral induction, in the gut, of Foxp3+ Treg specific for environmental antigens.
45. Mucida D, Park Y, Kim G, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007; 317:256-260.
46. Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198:1875-1886.
47. McMillan SJ, Xanthou G, Lloyd CM. Manipulation of allergen-induced airway remodeling by treatment with anti-TGF-beta antibody: effect on the Smad signaling pathway. J Immunol 2005; 174:5774-5780.
48. Kitani A, Fuss I, Nakamura K, et al. Transforming growth factor (TGF)-beta1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-beta1-mediated fibrosis. J Exp Med 2003; 198:1179-1188.
49. Hawrylowicz CM, O'Garra A. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol 2005; 5:271-283.
50. Hawrylowicz CM. Regulatory T cells and IL-10 in allergic inflammation. J Exp Med 2005; 202:1459-1463.
51. Urry Z, Xystrakis E, Hawrylowicz CM. Interleukin-10-secreting regulatory T cells in allergy and asthma. Curr Allergy Asthma Rep 2006; 6:363-371.
52. Akdis M, Verhagen J, Taylor A, et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004; 199:1567-1575.
53. Akdis CA, Blesken T, Akdis M, et al. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998; 102:98-106.
54. Xystrakis E, Kusumakar S, Boswell S, et al. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J Clin Invest 2006; 116:146-155. This paper shows the capacity of glucocorticoids to induce an IL-10 secreting T regulatory population in steroid sensitive, but not steroid insensitive, asthma patients. Importantly induction of this IL-10 secreting T regulatory population could be restored in steroid insensitive patients using the active form of vitamin D3.
55. Vieira PL, Christensen JR, Minaee S, et al. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J Immunol 2004; 172:5986-5993.
56. Adorini L. Immunomodulatory effects of vitamin D receptor ligands in autoimmune diseases. Int Immunopharmacol 2002; 2:1017-1028.
57. Peek EJ, Richards DF, Faith A, et al. Interleukin 10 secreting 'regulatory' T cells induced by glucocorticoids and beta2-agonists. Am J Respir Cell Mol Biol 2005; 33:105-111.
58. Segundo DS, Ruiz JC, Izquierdo M, et al. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation 2006; 82:550-557.
59. Isaacs JD. T cell immunomodulation: the Holy Grail of therapeutic tolerance. Curr Opin Pharmacol 2007; 2 Jul [Epub ahead of print]. This paper provides a comprehensive discussion of the pros and cons of novel Treg and immunomodulatory strategies in human immune-mediated disease.
60. Bluestone JA. Regulatory T-cell therapy: is it ready for the clinic? Nat Rev Immunol 2005; 5:343-349. This paper provides a comprehensive discussion of the pros and cons of novel Treg and immunomodulatory strategies in human immune-mediated disease.
61. Zheng Y, Rudensky AY. Foxp3 in control of the regulatory T cell lineage. Nat Immunol 2007; 8:457-462.
62. Tang Q, Henriksen KJ, Bi M, et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004; 199:1455-1465.
63. Sanchez-Fueyo A, Sandner S, Habicht A, et al. Specificity of CD4+CD25+ regulatory T cell function in alloimmunity. J Immunol 2006; 176:329-334.
64. Kuball J, Dossett ML, Wolfl M, et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 2007; 109:2331-2338.
65. Strickland DH, Stumbles PA, Zosky GR, et al. Reversal of airway hyperresponsiveness by induction of airway mucosal CD4+CD25+ regulatory T cells. J Exp Med 2006; 203:2649-2660.
66. Bluestone JA, Boehmer H. Regulatory T cells. Semin Immunol 2006; 18:77.
67. Vukmanovic-Stejic M, Zhang Y, Cook JE, et al. Human CD4+CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest 2006; 116:2423-2433. This paper is the first to address the longevity and turnover of natural Tregs in humans.
68. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol 2004; 113:1025-1034.
69. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006; 6:761-771.
70. Larche M, Wraith DC. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 2005; 11 (4 Suppl):S69-S76.
71. Niederberger V, Valenta R. Molecular approaches for new vaccines against allergy. Expert Rev Vaccines 2006; 5:103-110.
72. Maizels R. Regulation of the immune system in metazoan parasite infections. Novartis Found Symp 2007; 281:192-204.